Start typing to retrieve search suggestions. When suggestions are available use up and down arrows to review and ENTER to select. Continue typing to refine.
Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

Dabigatran etexilate 75 mg Hard Capsules

Active Ingredient:
dabigatran etexilate
Company:  
Celix Pharma Ltd See contact details
ATC code: 
B01AE07
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials
{arrow_left}
{arrow_right}
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine.
{info_black}
Last updated on emc: 02 Jul 2026
{pdf} View or print the patient leaflet as PDF

Below is a text only representation of the Patient Information Leaflet (ePIL).

The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on {phone} 0800 198 5000. The product code(s) for this leaflet is: PLGB 53835/0029.

{printer} Print patient leaflet as text only

Dabigatran etexilate 75 mg Hard Capsules

Package leaflet: Information for the patient

Dabigatran etexilate 75 mg Hard Capsules

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Dabigatran 75 mg Capsules are and what they are used for
2. What you need to know before you take Dabigatran 75 mg Capsules
3. How to take Dabigatran 75 mg Capsules
4. Possible side effects
5. How to store Dabigatran 75 mg Capsules
6. Contents of the pack and other information

1. What Dabigatran 75 mg Capsules are and what they are used for

Dabigatran 75 mg Capsules contain the active substance dabigatran etexilate and belongs to a group of medicines called anticoagulants. It works by blocking a substance in the body which is involved in blood clot formation.

Dabigatran 75 mg Capsules are used in adults to:

  • prevent the formation of blood clots in the veins after knee or hip replacement surgery.

Dabigatran 75 mg Capsules are used in children to:

  • treat blood clots and to prevent blood clots from reoccurring.

2. What you need to know before you take Dabigatran 75 mg Capsules
Do not take this medicine:
  • if you are allergic to dabigatran etexilate or any of the other ingredients of this medicine (listed in section 6).
  • if you have severely reduced kidney function.
  • if you are currently bleeding.
  • if you have a disease in an organ of the body that increases the risk of serious bleeding (e.g. stomach ulcer, injury or bleeding in the brain, recent surgery of the brain or eyes).
  • if you have an increased tendency to bleed. This may be inborn, of unknown cause or due to other medicines.
  • if you are taking medicines to prevent blood clotting (e.g. warfarin, rivaroxaban, apixaban or heparin), except when changing anticoagulant treatment, while having a venous or arterial line and you get heparin through this line to keep it open or while your heart beat is being restored to normal by a procedure called catheter ablation for atrial fibrillation.
  • if you have a severely reduced liver function or liver disease which could possibly cause death.
  • if you are taking oral ketoconazole or itraconazole, medicines to treat fungal infections.
  • if you are taking oral cyclosporine, a medicine to prevent organ rejection after transplantation.
  • if you are taking dronedarone, a medicine used to treat abnormal heart beat.
  • if you are taking a combination product of glecaprevir and pibrentasvir, an antiviral medicine used to treat hepatitis C.
  • if you have received an artificial heart valve which requires permanent blood thinning.

Warnings and precautions

Talk to your doctor or pharmacist before taking Dabigatran 75 mg Capsules.

You may also need to talk to your doctor during treatment with this medicine if you experience symptoms or if you have to undergo surgery.

Tell your doctor if you have or have had any medical conditions or illnesses, in particular any of those included in the following list:

  • if you have an increased bleeding risk, such as:
    • if you have been recently bleeding
    • if you have had a surgical tissue removal (biopsy) in the past month
    • if you have had a serious injury (e.g. a bone fracture, head injury or any injury requiring surgical treatment)
    • if you are suffering from an inflammation of the gullet or stomach
    • if you have problems with reflux of gastric juice into the gullet
    • if you are receiving medicines which could increase the risk of bleeding. See ‘Other medicines and dabigatran’ below
    • if you are taking anti-inflammatory medicines such as diclofenac, ibuprofen, piroxicam
    • if you are suffering from an infection of the heart (bacterial endocarditis)
    • if you know you have decreased kidney function, or you are suffering from dehydration (symptoms include feeling thirsty and passing reduced amounts of dark-coloured (concentrated) / foaming urine)
    • if you are older than 75 years
    • if you are an adult patient and weigh 50 kg or less
    • only if used for children: if the child has an infection around or within the brain
  • if you have had a heart attack or if you have been diagnosed with conditions that increase the risk to develop a heart attack.
  • if you have a liver disease that is associated with changes in the blood tests. The use of this medicine is not recommended in this case.

Take special care with dabigatran

Talk to your doctor if any of the below applies to you

  • if you need to have an operation:
    In this case dabigatran will need to be stopped temporarily due to an increased bleeding risk during and shortly after an operation. It is very important to take dabigatran before and after the operation exactly at the times you have been told by your doctor.
  • if an operation involves a catheter or injection into your spinal column (e.g. for epidural or spinal anaesthesia or pain reduction):
    • it is very important to take dabigatran before and after the operation exactly at the times you have been told by your doctor.
    • tell your doctor immediately if you get numbness or weakness of your legs or problems with your bowel or bladder after the end of anaesthesia, because urgent care is necessary.
  • if you fall or injure yourself during treatment, especially if you hit your head. Please seek urgent medical attention. You may need to be checked by a doctor, as you may be at increased risk of bleeding.
  • if you know that you have a disease called antiphospholipid syndrome (a disorder of the immune system that causes an increased risk of blood clots), tell your doctor who will decide if the treatment may need to be changed.

Other medicines and dabigatran

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

In particular you should tell your doctor before taking dabigatran, if you are taking one of the medicines listed below:

  • Medicines to reduce blood clotting (e.g. warfarin, phenprocoumon, acenocoumarol, heparin, clopidogrel, prasugrel, ticagrelor, rivaroxaban, acetylsalicylic acid).
  • Medicines to treat fungal infections (e.g. ketoconazole, itraconazole), unless they are only applied to the skin.
  • Medicines to treat abnormal heart beats (e.g. amiodarone, dronedarone, quinidine, verapamil). If you are taking amiodarone, quinidine or verapamil containing medicines, your doctor may tell you to use a reduced dose of dabigatran depending on the condition for which it is prescribed to you. See also section 3.
  • Medicines to prevent organ rejection after transplantation (e.g. tacrolimus, cyclosporine).
  • A combination product of glecaprevir and pibrentasvir (an antiviral medicine used to treat hepatitis C).
  • Anti-inflammatory and pain reliever medicines (e.g. acetylsalicylic acid, ibuprofen, diclofenac).
  • St. John’s wort, a herbal medicine for depression.
  • Antidepressant medicines called selective serotonin re-uptake inhibitors or serotonin-norepinephrine re-uptake inhibitors.
  • Rifampicin or clarithromycin (two antibiotics).
  • Anti-viral medicines for AIDS (e.g. ritonavir).
  • Certain medicines for treatment of epilepsy (e.g. carbamazepine, phenytoin).

Pregnancy and breast-feeding

The effects of dabigatran on pregnancy and the unborn child are not known. You should not take this medicine if you are pregnant unless your doctor advises you that it is safe to do so. If you are a woman of child-bearing age, you should avoid becoming pregnant while you are taking this medicine.

You should not breast-feed while you are taking dabigatran.

Driving and using machines

Dabigatran has no known effects on the ability to drive or use machines.

3. How to take Dabigatran 75 mg Capsules

Dabigatran 75 mg Capsules can be used in adults and children aged 8 years or older who are able to swallow the capsules whole. Dabigatran coated granules are available for the treatment of children below 12 years as soon as they are able to swallow soft food.

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Take dabigatran as recommended for the following conditions:

Prevention of blood clot formation after knee or hip replacement surgery

The recommended dose is 220 mg once a day (taken as 2 capsules of 110 mg).If your kidney function is decreased by more than half or if you are 75 years of age or older, the recommended dose is 150 mg once a day (taken as 2 capsules of 75 mg).

If you are taking amiodarone, quinidine or verapamil containing medicines the recommended dose is 150 mg once a day (taken as 2 capsules of 75 mg).

If you are taking verapamil containing medicines and your kidney function is decreased by more than half, you should be treated with a reduced dose of 75 mg dabigatran because your bleeding risk may be increased.

For both surgery types, treatment should not be started if there is bleeding from the site of operation. If the treatment cannot be started until the day after surgery, dosing should be started with 2 capsules once a day.

After knee replacement surgery

You should start treatment with dabigatran within 1-4 hours after surgery finishes, taking a single capsule. Thereafter two capsules once a day should be taken for a total of 10 days.

After hip replacement surgery

You should start treatment with dabigatran within 1-4 hours after surgery finishes, taking a single capsule. Thereafter two capsules once a day should be taken for a total of 28-35 days.

Treatment of blood clots and prevention of blood clots from reoccurring in children

Dabigatran should be taken twice daily, one dose in the morning and one dose in the evening, at approximately the same time every day. The dosing interval should be as close to 12 hours as possible.

The recommended dose depends on weight and age. Your doctor will determine the correct dose. Your doctor may adjust the dose as treatment progresses. Keep using all other medicines, unless your doctor tells you to stop using any.

Table 1 shows single and total daily dabigatran doses in milligrams (mg). The doses depend on weight in kilograms (kg) and age in years of the patient.

Table 1: Dosing table for dabigatran capsules

Weight in kg 11 to < 13 / Age in years 8 to < 9

Single dose 75mg / Total daily dose 150mg

Weight in kg 13 to < 16 / Age in years 8 to < 11

Single dose 110mg / Total daily dose 220mg

Weight in kg 16 to < 21 / Age in years 8 to < 14

Single dose 110mg / Total daily dose 220mg

Weight in kg 21 to < 26 / Age in years 8 to < 16

Single dose 150mg / Total daily dose 300mg

Weight in kg 26 to < 31 / Age in years 8 to < 18

Single dose 150mg / Total daily dose 300mg

Weight in kg 31 to < 41 / Age in years 8 to < 18

Single dose 185mg / Total daily dose 370mg

Weight in kg 41 to < 51 / Age in years 8 to < 18

Single dose 220mg / Total daily dose 440mg

Weight in kg 51 to < 61 / Age in years 8 to < 18

Single dose 260mg / Total daily dose 520mg

Weight in kg 61 to < 71 / Age in years 8 to< 18

Single dose 300mg / Total daily dose 600mg

Weight in kg 71 to < 81 / Age in years 8 to < 18

Single dose 300mg / Total daily dose 600mg

Weight in kg > 81 / Age in years 10 to < 18

Single dose 300mg / Total daily dose 600mg

Single doses requiring combinations of more than one capsule:

300 mg: two 150 mg capsules or

four 75 mg capsules

260 mg: one 110 mg plus one 150 mg capsule or

one 110 mg plus two 75 mg capsules

220 mg: two 110 mg capsules

185 mg: one 75 mg plus one 110 mg capsule

150 mg: one 150 mg capsule or

two 75 mg capsules

How to take dabigatran

Dabigatran can be taken with or without food. The capsule should be swallowed whole with a glass of water, to ensure delivery to the stomach. Do not break, chew, or empty the pellets from the capsule since this may increase the risk of bleeding.

Change of anticoagulant treatment

Without specific guidance from your doctor do not change your anticoagulant treatment.

If you take more dabigatran than you should

Taking too much of this medicine increases the risk of bleeding. Contact your doctor immediately if you have taken too many capsules. Specific treatment options are available.

If you forget to take dabigatran

Prevention of blood clot formation after knee or hip replacement surgery

Continue with your remaining daily doses of dabigatran at the same time of the next day. Do not take a double dose to make up for a forgotten dose.

Treatment of blood clots and prevention of blood clots from reoccurring in children

A forgotten dose can still be taken up to 6 hours prior to the next due dose.

A missed dose should be omitted if the remaining time is below 6 hours prior to the next due dose. Do not double a dose to make up for a forgotten dose.

If you stop taking dabigatran

Take dabigatran exactly as prescribed. Do not stop taking this medicine without talking to your doctor first, because the risk of developing a blood clot could be higher if you stop treatment too early.

Contact your doctor if you experience indigestion after taking dabigatran.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Dabigatran affects blood clotting, so most side effects are related to signs such as bruising or bleeding.

Major or severe bleeding may occur, these constitute the most serious side effects and, regardless of location, may become disabling, life-threatening or even lead to death. In some cases these bleedings may not be obvious.

If you experience any bleeding event that does not stop by itself or if you experience signs of excessive bleeding (exceptional weakness, tiredness, paleness, dizziness, headache or unexplained swelling) consult your doctor immediately. Your doctor may decide to keep you under closer observation or change your medicine.

Tell your doctor immediately, if you experience a serious allergic reaction which causes difficulty in breathing or dizziness.

Possible side effects are listed below, grouped by how likely they are to happen.

Prevention of blood clot formation after knee or hip replacement surgery

Common (may affect up to 1 in 10 people):

  • A fall in the amount of haemoglobin in the blood (the substance in the red blood cells).
  • Unusual laboratory test results on liver function.

Uncommon (may affect up to 1 in 100 people):

  • Bleeding may happen from the nose, into the stomach or bowel, from penis/vagina or urinary tract (incl. blood in the urine that stains the urine pink or red), from piles, from the rectum, under the skin, into a joint, from or after an injury or after an operation.
  • Haematoma formation or bruising occurring after an operation.
  • Blood detected in the stools by a laboratory test.
  • A fall in the number of red cells in the blood.
  • A decrease in the proportion of blood cells.
  • Allergic reaction.
  • Vomiting.
  • Frequent loose or liquid bowel movements.
  • Feeling sick.
  • Wound secretion (liquid exuding from the surgical wound).
  • Liver enzymes increased.
  • Yellowing of the skin or whites of the eyes, caused by liver or blood problems.

Rare (may affect up to 1 in 1,000 people):

  • Bleeding.
  • Bleeding may happen in the brain, from a surgical incision, from the site of entry of an injection or from the site of entry of a catheter into a vein.
  • Blood-stained discharge from the site of entry of a catheter into a vein.
  • Coughing of blood or blood stained sputum.
  • A fall in the number of platelets in the blood.
  • A fall in the number of red cells in the blood after an operation.
  • Serious allergic reaction which causes difficulty in breathing or dizziness.
  • Serious allergic reaction which causes swelling of the face or throat.
  • Skin rash notable for dark red, raised, itchy bumps caused by an allergic reaction.
  • Sudden change of the skin which affects its colour and appearance.
  • Itching.
  • Ulcer in the stomach or bowel (incl. ulcer in the gullet).
  • Inflammation of the gullet and stomach.
  • Reflux of gastric juice into the gullet.
  • Belly ache or stomach ache.
  • Indigestion.
  • Difficulty in swallowing.
  • Fluid exiting a wound.
  • Fluid exiting a wound after an operation.

Not known (frequency cannot be estimated from the available data):

  • Difficulty in breathing or wheezing.
  • Decreases in the number or even lack of white blood cells (which help to fight infections)
  • Hair loss.

Treatment of blood clots and prevention of blood clots from reoccurring in children

Common (may affect up to 1 in 10 people):

  • A fall in the number of red cells in the blood.
  • A fall in the number of platelets in the blood.
  • Skin rash notable for dark red, raised, itchy bumps caused by an allergic reaction.
  • Sudden change of the skin which affects its colour and appearance.
  • Haematoma formation.
  • Nosebleed.
  • Reflux of gastric juice into the gullet.
  • Vomiting.
  • Feeling sick.
  • Frequent loose or liquid bowel movements.
  • Indigestion.
  • Hair loss.
  • Liver enzymes increased.

Uncommon (may affect up to 1 in 100 people):

  • Decrease in the number of white blood cells (which help to fight infections).
  • Bleeding may happen into the stomach or bowel, from the brain, from the rectum, from penis/vagina or urinary tract (incl. blood in the urine that stains the urine pink or red), or under the skin.
  • A fall in the amount of haemoglobin in the blood (the substance in the red blood cells).
  • A decrease in the proportion of blood cells.
  • Itching.
  • Coughing of blood or blood stained sputum.
  • Belly ache or stomach ache.
  • Inflammation of the gullet and stomach.
  • Allergic reaction.
  • Difficulty in swallowing.
  • Yellowing of the skin or whites of the eyes, caused by liver or blood problems.

Not known (frequency cannot be estimated from the available data):

  • Lack of white blood cells (which help to fight infections).
  • Serious allergic reaction which causes difficulty in breathing or dizziness.
  • Serious allergic reaction which causes swelling of the face or throat.
  • Difficulty in breathing or wheezing.
  • Bleeding.
  • Bleeding may happen into a joint or from an injury, from a surgical incision, or from the site of entry of an injection or from the site of entry of a catheter into a vein.
  • Bleeding may happen from piles.
  • Ulcer in the stomach or bowel (incl. ulcer in the gullet).
  • Unusual laboratory test results on liver function.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Dabigatran 75 mg Capsules

Keep this medicine out of the sight and reach of children.

This medicine does not require any special temperature storage conditions. Store in the original package in order to protect from moisture.

Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information
What Dabigatran 75 mg Capsules contain
  • The active substance is dabigatran. Each hard capsule contains 75 mg dabigatran etexilate (as mesilate)
  • The other ingredients are tartaric acid, acacia, hypromellose, talc, dimethicone and hydroxypropylcellulose
  • The capsule shell contains titanium dioxide, hypromellose, carrageenan and potassium chloride
  • The black printing ink contains shellac, black iron oxide and potassium hydroxide

What Dabigatran 75 mg Capsules look like and contents of the pack

Dabigatran 75 mg Capsules are hard capsules (approximately 18 mm long) with an opaque white cap and an opaque white body. The capsule body is printed with 75.

This medicine is available in packs containing 60 hard capsules in aluminium blisters.

Marketing Authorisation Holder
Celix Pharma Ltd
12 Constance Street
London
E16 2DQ
United Kingdom

Manufacturer
Celix Pharma Ltd
1st Floor
Building 2
Croxley Business Park
Watford
WD18 8YA
United Kingdom

If you are blind or partially sighted and require this leaflet in a different format, call 0800 669 6825 or contact [email protected].

This leaflet was last revised in November 2024.

Celix Pharma Ltd
Company image
Address
12 Constance Street, International House, London, E16 2DQ, UK
Medical Information e-mail
[email protected]
Medical Information Direct Line
0800 669 6825
Telephone
0800 669 6825
WWW
http://www.celixpharma.com/
Customer Care direct line
+44 (0)203 105 6525
E-mail
[email protected]